OBI Pharma Discontinues Phase 1/2 Study Of Antibody-OBI 888

OBI Pharma, a Taiwan biopharma company, said it has discontinued the phase 1/2 Study for OBI 888, a Globo H antibody.

According to the company, preliminary data from phase 1/2 study demonstrated that OBI 888 is a safe and well tolerated product and showed some trends of efficacy. However, due to the higher antibody amount required for the OBI-888 treatment compared to the ADC, OBI-999, and an unexpected low drug yield at the large manufacturing scale, OBI-888 no longer fulfills goal of developing cost-effective therapies for cancer patients.

The company said it will focus on novel cancer pipeline under phase 3 (Adagloxad Simolenin-vaccine) and phase 2 (OBI 999-ADC, OBI 833-vaccine and OBI 3424-small molecule) clinical development.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Stocks staged a significant recovery attempt after pulling back sharply in early trading on Wednesday but still ended the day modestly lower. The major averages gave back ground after moving sharply higher over the two previous sessions. Three scientists have shared the Nobel Prize for Chemistry for their work that led to the development of linking molecules together, known as click chemistry, and bioorthogonal chemistry. Morten Meldal and K. Barry Sharpless have laid the foundation for a functional form of chemistry - click chemistry - in which molecular building blocks snap together quickly and efficiently. Carolyn R. Bertozzi The Institute for Supply Management released a report on Wednesday showing a modest slowdown in the pace of growth in U.S. service sector activity in the month of September. The ISM said its services PMI edged down to 56.7 in September from 56.9 in August, although a reading above 50 still indicates growth in the sector.
Follow RTT